Drug Product Leadership Group Webinar: “Current Utility of Extemporaneous Formulations”
The development of innovative and cost effective, pharmaceutical agents has placed a premium on delivering the maximum benefit and value to the patient. A key element of this goal is reducing the cycle time and resources necessary to achieve critical decision points within a product development plan (e.g. early read outs on efficacy and tolerability). Extemporaneous formulations, or formulations prepared at the clinical study site, are a set of common techniques utilized to address clinical development needs in a low cost/high value manner; and are of particular value when the clinical study in question does not need to be supported by a commercial image.
A working group within the Innovation and Quality Consortia, Drug Product Leadership group has surveyed member companies on their extemporaneous formulations practices. The subject webinar will summarize these survey results, focusing on current utility and best practices for formulations extemporaneously prepared at the clinical site.
This webinar will be from 11:00AM-12:00PM ET. It is open to members of all IQ Consortium committees.